Rezolute Bio
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us
  • Therapeutic Focus
    • Pipeline
    • RZ358
    • RZ402
    • Publications
    • Data Presentations
  • For Patients
    • Overview
    • Living with HI
    • Living with DME
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Join Us
    • Our Mission
    • Open Positions
    • Benefits
  • Contact Us
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info

Press Releases

  • News & Events

  • Overview
  • IR Calendar
Sep 14, 2023 4:05pm EDT

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

Sep 06, 2023 7:00am EDT

Rezolute to Participate in Upcoming Investor Conferences in September

Jun 27, 2023 4:05pm EDT

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

May 11, 2023 4:05pm EDT

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

Mar 23, 2023 4:50pm EDT

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

Mar 08, 2023 7:00am EST

Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

Feb 10, 2023 4:05pm EST

Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

Dec 15, 2022 7:00am EST

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

Nov 09, 2022 4:05pm EST

Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress

Nov 01, 2022 7:00am EDT

Rezolute to Present at the Jefferies London Healthcare Conference

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …12
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
rezolute logo

©2023 Rezolute, Inc.

Explore

  • Therapeutic Focus
  • For Patients
  • About
  • Join Us
  • Contact Us
  • Investors & Media

Contact

Corporate Headquarters

275 Shoreline Drive
Suite 500
Redwood City, CA 94065
+1 (650) 206-4507
info@rezolutebio.com

Investor Relations

Investor Relations Contacts

Legal

  • Terms of Use
  • Privacy Policy
MENU
  • Therapeutic Focus
    • Pipeline
    • RZ358
    • RZ402
    • Publications
    • Data Presentations
  • For Patients
    • Overview
    • Living with HI
    • Living with DME
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Join Us
    • Our Mission
    • Open Positions
    • Benefits
  • Contact Us
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News & Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info